Effect of resveratrol capsules on knee osteoarthritis symptoms and specific markers of joint breakdown

A pilot clinical study of the effect of resveratrol on the serum level of Coll 2-1 and Aggrecan biomarkers in patients with knee osteoarthritis; a non-randomized open-labelled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN75392625

Enrollment

Registered

2020-09-09

Start date

2020-01-10

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis Musculoskeletal Diseases Gonarthrosis [arthrosis of knee]

Interventions

This is a single-arm non-randomized non-controlled open labelled clinical trial. The study will be a 12-week of administration of oral resveratrol (500 mg/day in a single dose) alone in patients with

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild to moderate OA at both screening and baseline visits, as defined by the up-to-date revised American College of Rheumatology (ACR) criteria for diagnosis of knee OA

Exclusion criteria

Exclusion criteria: 1. Patients with a history of rheumatoid arthritis, gout, severe ischaemic heart disease, heart failure, hepatic failure, renal failure 2. Consumption of non-steroidal anti-inflammatory drugs or corticosteroid drugs within 4 weeks of study, intra-articular injection within 3 months prior to the study recruitment 3. Pregnant or desire to become pregnant, or lactating women

Design outcomes

Primary

Measure	Time frame
1. Specific biomarkers of osteoarthritis (Coll 2-1 and Aggrecan) measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer instructions before treatment (at day 0) and after 90 days of treatment. 2. Biomarkers of inflammation including TNF-a, IL-1ß, IL-6 (measured using ELISA kit according to the manufacturer instructions) and hsCRP and the complement system (measured by spectrophotometry utilizing ready-made kits and Roche/Hitachi cobas c systems) measured at baseline at Day 0 (pre-treatment) and at day 90 (post treatment) 3. Standard haematological profile (measured utilizing the Swelab Alfa Plus system) and both liver and kidney functions markers (liver and kidney function tests), and lipid profiles measured spectrophotometrically using the clinical chemistry analyzer Cobas c 311 and ready-made kits according to the manufacturer’s recommendations for evaluating safety and tolerability of resveratrol at baseline and at the end of the treatment	—

Measure

Time frame

1. Specific biomarkers of osteoarthritis (Coll 2-1 and Aggrecan) measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer instructions before treatment (at day 0) and after 90 days of treatment. 2. Biomarkers of inflammation including TNF-a, IL-1ß, IL-6 (measured using ELISA kit according to the manufacturer instructions) and hsCRP and the complement system (measured by spectrophotometry utilizing ready-made kits and Roche/Hitachi cobas c systems) measured at baseline at Day 0 (pre-treatment) and at day 90 (post treatment) 3. Standard haematological profile (measured utilizing the Swelab Alfa Plus system) and both liver and kidney functions markers (liver and kidney function tests), and lipid profiles measured spectrophotometrically using the clinical chemistry analyzer Cobas c 311 and ready-made kits according to the manufacturer’s recommendations for evaluating safety and tolerability of resveratrol at baseline and at the end of the treatment

—

Secondary

Measure	Time frame
Symptoms of osteoarthritis measured using the adopted scoring systems of visual analogue scale for pain (VAS) and Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline (day 0), 1, 2 and 3 months	—

Countries

Iraq

Contacts

Public ContactBushra Marouf

bushra.marouf@univsul.edu.iq+964 (0)7701562796

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026